drugset / Trial / NCT00426803

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00426803

Phase 2 Completed 400 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

Timeline

Start
2002-08
Primary completion
2004-06
Completion
2004-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject eptacog alfa (activated) Protein / enzyme biologic 40 ug/kg
Subject eptacog alfa (activated) Protein / enzyme biologic 80 ug/kg
Subject eptacog alfa (activated) Protein / enzyme biologic 160 ug/kg